Rapid Micro Biosystems, Inc. (RPID) Reports Q3 Loss, Misses Revenue Estimates

Core Insights - Rapid Micro Biosystems, Inc. reported a quarterly loss of $0.26 per share, consistent with the Zacks Consensus Estimate, and the same as the loss reported a year ago [1] - The company generated revenues of $7.84 million for the quarter ended September 2025, slightly missing the Zacks Consensus Estimate by 0.79%, but showing an increase from $7.6 million year-over-year [2] - The stock has increased approximately 205.6% since the beginning of the year, significantly outperforming the S&P 500's gain of 14.3% [3] Financial Performance - The company has surpassed consensus EPS estimates two times over the last four quarters [1] - Revenue estimates for the upcoming quarter are projected at $9.8 million, with a consensus EPS estimate of -$0.23, while the current fiscal year is expected to generate $32.2 million in revenue with an EPS estimate of -$0.99 [7] Market Outlook - The current Zacks Rank for Rapid Micro Biosystems is 3 (Hold), indicating expected performance in line with the market in the near future [6] - The Medical - Instruments industry, to which the company belongs, is currently in the top 33% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]